Skip to main content

Table 1 General information

From: Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case–control study

Pt Sex Onset age (years) (岁) Final diagnosis Treatment Time of CAD recovery Duration of follow-up (month) Result
1 F 10.5 CAEBV L-DEP Non-recovered 8.0 Alive
2 M 6.3 CAEBV Abandon Non-recovered 12.0 Alive
3 M 12.2 CAEBV, HLH Abandon Non-recovered 13.0 Alive
4 F 5.8 CAEBV Abandon Non-recovered 27.0 Alive
5 M 14.3 CAEBV L-DEP 18 days 28.0 Alive
6 M 3.2 CAEBV L-DEP, HSCT 68 days 28.0 Alive
7 M 7.6 CAEBV L-DEP, HSCT Non-recovered 6.0 Dead
8 F 4.3 CAEBV L-DEP, HSCT Non-recovered 48.0 Alive
9 F 2.8 CAEBV,HLH L-DEP Non-recovered 8.0 Alive
10 M 5.0 CAEBV, HLH L-DEP, HSCT 21 days 30.0 Alive
  1. Pt patient, CAEBV chronic active Epstein–Barr virus infection, HLH hemophagocytic lymphohistiocytosis, CAD coronary artery dilatation, L-DEP PEG-Aspegaspargase, doxorubicin, etoposide and methylprednisolone, time of CAD recovery the time from discovery of CAD to recovery